. Inca, Les cancers en France -Edition 2013 -Publications -Institut National Du Cancer. at <http://www.e-cancer.fr/publications/69-epidemiologie/758-les-cancers-en-france-edition-2013> 2. Bigot, F. et al. Évolution épidémiologique du cancer broncho-pulmonaire en France et en, Europe. Rev. Mal. Respir. Actual, vol.5, pp.321-324, 2013.

D. R. Youlden, S. M. Cramb, and P. Baade, The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends, Journal of Thoracic Oncology, vol.3, issue.8, pp.819-831, 2008.
DOI : 10.1097/JTO.0b013e31818020eb

. Globocan-2012, Fact Sheets by Population. at <http://globocan.iarc.fr/Pages//fact_sheets_ population.aspx> 5. INCa. Aspects économiques des coûts du cancer en France, pp.1286-4265, 2007.

M. Malvezzi, P. Bertuccio, F. Levi, C. L. Vecchia, and E. Negri, European cancer mortality predictions for the year 2014, Annals of Oncology, vol.25, issue.8, pp.1650-1656, 2014.
DOI : 10.1093/annonc/mdu138

F. Binder-foucard, Cancer incidence and mortality in France over the 1980?2012 period: Solid tumors. Rev. D'Épidémiologie Santé Publique 62, pp.95-108, 2014.

. American-lung-association, Lung Cancer Fact Sheet American Lung Association (2014) at <http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-factsheet .html> 9. Horner, J. W. SEER Cancer Statistics Review 1975-2006 -Previous Version -SEER Cancer Statistics, 2006.

. Beck, Tendances 76 -Les niveaux d'usage des drogues en France en 2010, 2011.

C. Hill, Tobacco epidemiology, Rev. Prat, vol.62, issue.325, pp.327-329, 2012.

H. Health and . Services, Smoking and Tobacco Use; 50th Anniversary Surgeon General's Report. Smoking and Tobacco Use, 2012.

M. Öberg, M. S. Jaakkola, A. Woodward, A. Peruga, and A. Prüss-ustün, Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries, The Lancet, vol.377, issue.9760, pp.139-146, 2011.
DOI : 10.1016/S0140-6736(10)61388-8

M. Talikka, Genomic impact of cigarette smoke, with application to three smoking-related diseases, Critical Reviews in Toxicology, vol.107, issue.10, pp.877-889, 2012.
DOI : 10.1165/rcmb.2007-0379OC

X. Guo, Mutagenicity of 11 cigarette smoke condensates in two versions of the mouse lymphoma assay, Mutagenesis, vol.26, issue.2, pp.273-281, 2011.
DOI : 10.1093/mutage/geq083

L. Anna, Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary, Mutagenesis, vol.24, issue.6, pp.475-480, 2009.
DOI : 10.1093/mutage/gep031

R. Doll, Mortality in relation to smoking: 50 years' observations on male British doctors, BMJ, vol.328, issue.7455, pp.1519-1519, 2004.
DOI : 10.1136/bmj.38142.554479.AE

A. Parsons, A. Daley, R. Begh, and P. Aveyard, Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis, BMJ, vol.340, issue.jan21 1, pp.5569-5569, 2010.
DOI : 10.1136/bmj.b5569

S. Aldington, Cannabis use and risk of lung cancer: a case-control study, European Respiratory Journal, vol.31, issue.2, pp.280-286, 2008.
DOI : 10.1183/09031936.00065707

M. Joshi, A. Joshi, and T. Bartter, Marijuana and lung diseases, Current Opinion in Pulmonary Medicine, vol.20, issue.2, pp.173-179, 2014.
DOI : 10.1097/MCP.0000000000000026

G. Dixsaut, Cancer broncho-pulmonaire, nouvelle approche ??pid??miologique, Revue des Maladies Respiratoires Actualit??s, vol.5, issue.5, pp.581-590, 2013.
DOI : 10.1016/S1877-1203(13)70456-7

J. H. Lubin, Lung Cancer in Radon-Exposed Miners and Estimation of Risk From Indoor Exposure, JNCI Journal of the National Cancer Institute, vol.87, issue.11, pp.817-827, 1995.
DOI : 10.1093/jnci/87.11.817

O. Catelinois, Lung Cancer Attributable to Indoor Radon Exposure in France: Impact of the Risk Models and Uncertainty Analysis, Environmental Health Perspectives, vol.114, issue.9, pp.1361-1366, 2006.
DOI : 10.1289/ehp.9070

URL : https://hal.archives-ouvertes.fr/inserm-00138827

Y. Ngamwong, Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis, PLOS ONE, vol.153, issue.8, 2015.
DOI : 10.1371/journal.pone.0135798.s003

J. Mazieres, I. Rouquette, and L. Brouchet, Cancer bronchique de la femme et de la femme enceinte : vers une origine hormonale ?, Revue des Maladies Respiratoires, vol.24, issue.8, pp.983-997, 2007.
DOI : 10.1016/S0761-8425(07)92763-1

W. D. Travis, The 2015 World Health Organization Classification of Lung Tumors, Journal of Thoracic Oncology, vol.10, issue.9, pp.10-10970000000000000630, 2015.
DOI : 10.1097/JTO.0000000000000630

W. D. Travis, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-285, 2011.
DOI : 10.1097/JTO.0b013e318206a221

URL : https://hal.archives-ouvertes.fr/inserm-00561753

J. Yim, Histologic features are important prognostic indicators in early stages lung adenocarcinomas, Modern Pathology, vol.67, issue.2, pp.233-241, 2006.
DOI : 10.1038/modpathol.3800734

P. F. Goldstraw, The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-714, 2007.
DOI : 10.1097/JTO.0b013e31812f3c1a

T. Holbro, G. Civenni, and N. Hynes, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003.
DOI : 10.1016/S0014-4827(02)00099-X

R. N. Jorissen, Epidermal growth factor receptor: mechanisms of activation and signalling, Experimental Cell Research, vol.284, issue.1, pp.31-53, 2003.
DOI : 10.1016/S0014-4827(02)00098-8

K. Imai and A. Takaoka, Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer, vol.23, issue.9, pp.714-727, 2006.
DOI : 10.1038/nrc1913

A. Ruppert, Un regard simple sur la biologie du cancer bronchique??: EGFR, Revue des Maladies Respiratoires, vol.28, issue.4, pp.565-577, 2011.
DOI : 10.1016/j.rmr.2011.03.005

M. Scaltriti and J. Baselga, The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy, Clinical Cancer Research, vol.12, issue.18, pp.5268-5272, 2006.
DOI : 10.1158/1078-0432.CCR-05-1554

D. K. Moscatello, Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors, Cancer Res, vol.55, pp.5536-5539, 1995.

J. Mendelsohn and J. Baselga, The EGF receptor family as targets for cancer therapy. Publ. Online 08 Febr, 2001.

J. Zha, H. Harada, E. Yang, J. Jockel, and S. J. Korsmeyer, Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL, Cell, vol.87, issue.4, pp.619-628, 1996.
DOI : 10.1016/S0092-8674(00)81382-3

C. K. Goldman, Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology., Molecular Biology of the Cell, vol.4, issue.1, pp.121-133, 1993.
DOI : 10.1091/mbc.4.1.121

R. Nishikawa, A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity., Proc. Natl. Acad. Sci. 91, pp.7727-7731, 1994.
DOI : 10.1073/pnas.91.16.7727

S. V. Sharma, D. W. Bell, J. Settleman, and D. A. Haber, Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-181, 2007.
DOI : 10.1038/nrc2088

J. Cadranel, A. Ruppert, M. Beau-faller, and M. Wislez, Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma, Critical Reviews in Oncology/Hematology, vol.88, issue.3, pp.477-493, 2013.
DOI : 10.1016/j.critrevonc.2013.06.009

M. Fukuoka, Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.21, issue.12, pp.2237-2246, 2003.
DOI : 10.1200/JCO.2003.10.038

M. G. Kris, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003.
DOI : 10.1001/jama.290.16.2149

T. J. Lynch, Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004.
DOI : 10.1056/NEJMoa040938

J. G. Paez, EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science, vol.304, issue.5676, pp.1497-1500, 2004.
DOI : 10.1126/science.1099314

J. R. Goffin and K. Zbuk, Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline, Clinical Therapeutics, vol.35, issue.9, pp.1282-1303, 2013.
DOI : 10.1016/j.clinthera.2013.08.007

S. Forbes, COSMIC 2005, British Journal of Cancer, vol.57, issue.2, pp.318-322, 2005.
DOI : 10.1126/science.1096096

A. F. Gazdar, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, vol.19, pp.24-31, 2009.
DOI : 10.1016/j.cell.2006.05.013

A. R. Li, EGFR Mutations in Lung Adenocarcinomas, The Journal of Molecular Diagnostics, vol.10, issue.3, pp.242-248, 2008.
DOI : 10.2353/jmoldx.2008.070178

C. Yun, Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity, Cancer Cell, vol.11, issue.3, pp.217-227, 2007.
DOI : 10.1016/j.ccr.2006.12.017

H. Shigematsu, Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers, JNCI Journal of the National Cancer Institute, vol.97, issue.5, pp.339-346, 2005.
DOI : 10.1093/jnci/dji055

T. S. Mok, Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-957, 2009.
DOI : 10.1056/NEJMoa0810699

D. Pham, Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas, Journal of Clinical Oncology, vol.24, issue.11, pp.1700-1704, 2006.
DOI : 10.1200/JCO.2005.04.3224

D. W. Bell, Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non???Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials, Journal of Clinical Oncology, vol.23, issue.31, pp.8081-8092, 2005.
DOI : 10.1200/JCO.2005.02.7078

F. Cappuzzo, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.521-529, 2010.
DOI : 10.1016/S1470-2045(10)70112-1

F. A. Shepherd, Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-132, 2005.
DOI : 10.1056/NEJMoa050753

A. Kumar, E. T. Petri, B. Halmos, and T. J. Boggon, Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1742-1751, 2008.
DOI : 10.1200/JCO.2007.12.1178

A. Hata, Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.5, issue.10, pp.1524-1528, 2010.
DOI : 10.1097/JTO.0b013e3181e8b3c5

K. Ohtsuka, V843I Germ-Line Mutation, Journal of Clinical Oncology, vol.29, issue.8, pp.191-192, 2011.
DOI : 10.1200/JCO.2010.31.4492

G. R. Oxnard, Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions, Journal of Thoracic Oncology, vol.8, issue.2, pp.179-184, 2013.
DOI : 10.1097/JTO.0b013e3182779d18

D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995.
DOI : 10.1016/1040-8428(94)00144-I

N. I. Lindeman, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology, Archives of Pathology & Laboratory Medicine, vol.137, issue.6, pp.828-860, 2013.
DOI : 10.5858/arpa.2012-0720-OA.s1

R. Perez, T. Crombet, J. Leon, and E. Moreno, A view on EGFR-targeted therapies from the oncogene-addiction perspective, Frontiers in Pharmacology, vol.4, 2013.
DOI : 10.3389/fphar.2013.00053

C. J. Sweeney, Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594, Cancer, vol.11, issue.10, pp.2639-2647, 2001.
DOI : 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8

R. Rosell, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, vol.13, issue.3, pp.239-246, 2012.
DOI : 10.1016/S1470-2045(11)70393-X

Y. Wu, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, openlabel , ENSURE study, Ann. Oncol, vol.270, 2015.

G. J. Riely, Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib, Clinical Cancer Research, vol.12, issue.3, pp.839-844, 2006.
DOI : 10.1158/1078-0432.CCR-05-1846

T. Mitsudomi, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet Oncology, vol.11, issue.2, pp.121-128, 2010.
DOI : 10.1016/S1470-2045(09)70364-X

M. Maemondo, Gefitinib or Chemotherapy for Non???Small-Cell Lung Cancer with Mutated EGFR, New England Journal of Medicine, vol.362, issue.25, pp.2380-2388, 2010.
DOI : 10.1056/NEJMoa0909530

J. Han, First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung, Journal of Clinical Oncology, vol.30, issue.10, pp.1122-1128, 2012.
DOI : 10.1200/JCO.2011.36.8456

D. Li, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, vol.6, issue.34, pp.4702-4711, 2008.
DOI : 10.1016/j.ccr.2006.05.023

J. Köhler, M. Schuler, and . Afatinib, Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review, Onkologie, vol.36, issue.9, pp.5-5, 2013.
DOI : 10.1159/000354627

Y. Wu, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, The Lancet Oncology, vol.15, issue.2, pp.213-222, 2014.
DOI : 10.1016/S1470-2045(13)70604-1

L. V. Sequist, Mutations, Journal of Clinical Oncology, vol.31, issue.27, pp.3327-3334, 2013.
DOI : 10.1200/JCO.2012.44.2806

J. C. Yang and -. , Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) ASCO Meet, Abstr, vol.32, p.8004, 2014.

C. Zhou, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, The Lancet Oncology, vol.12, issue.8, pp.735-742, 2011.
DOI : 10.1016/S1470-2045(11)70184-X

A. Inoue, First-Line Gefitinib for Patients With Advanced Non???Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy, Journal of Clinical Oncology, vol.27, issue.9, pp.1394-1400, 2009.
DOI : 10.1200/JCO.2008.18.7658

R. Rosell, Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, New England Journal of Medicine, vol.361, issue.10, pp.958-967, 2009.
DOI : 10.1056/NEJMoa0904554

F. Petrelli, K. Borgonovo, M. Cabiddu, and S. Barni, Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non???Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials, Clinical Lung Cancer, vol.13, issue.2, pp.107-114, 2012.
DOI : 10.1016/j.cllc.2011.08.005

C. K. Lee, Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis, JNCI Journal of the National Cancer Institute, vol.105, issue.9, pp.595-605, 2013.
DOI : 10.1093/jnci/djt072

P. A. Jänne, Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial, Journal of Clinical Oncology, vol.30, issue.17, pp.2063-2069, 2012.
DOI : 10.1200/JCO.2011.40.1315

T. Seto, Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, The Lancet Oncology, vol.15, issue.11, pp.1236-1244, 2014.
DOI : 10.1016/S1470-2045(14)70381-X

Y. Rukazenkov, Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? [Review]. Anti-Cancer Drugs Novemb, pp.856-866, 2009.

J. Li, M. Zhao, P. He, M. Hidalgo, and S. D. Baker, Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes, Clinical Cancer Research, vol.13, issue.12, pp.3731-3737, 2007.
DOI : 10.1158/1078-0432.CCR-07-0088

T. Ciuleanu, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, The Lancet, vol.374, issue.9699, pp.1432-1440, 2009.
DOI : 10.1016/S0140-6736(09)61497-5

N. Hanna, Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non???Small-Cell Lung Cancer Previously Treated With Chemotherapy, Journal of Clinical Oncology, vol.22, issue.9, pp.1589-1597, 2004.
DOI : 10.1200/JCO.2004.08.163

N. Thatcher, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), The Lancet, vol.366, issue.9496, pp.1527-1537, 2005.
DOI : 10.1016/S0140-6736(05)67625-8

M. D. Maio, Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.11, pp.1836-1843, 2009.
DOI : 10.1200/JCO.2008.17.5844

. Inca, Prise en charge thérapeutique du cancer du poumon non à petites cellules : synthèse des recommandations at <http://www.e-cancer.fr/component/docman/doc_download/9609- prise-en-charge-therapeutique-du-cancer-du-poumon-non-a-petites-cellules-synthese-des- recommandations>, 2010.

A. Ribas, Tumor Immunotherapy Directed at PD-1, New England Journal of Medicine, vol.366, issue.26, pp.2517-2519, 2012.
DOI : 10.1056/NEJMe1205943

J. Soria, A. Marabelle, J. R. Brahmer, and S. Gettinger, Immune Checkpoint Modulation for Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.21, issue.10, pp.2256-2262, 2015.
DOI : 10.1158/1078-0432.CCR-14-2959

N. Chen, Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation, Journal of Thoracic Oncology, vol.10, issue.6, pp.910-923, 2015.
DOI : 10.1097/JTO.0000000000000500

A. G. Pallis, Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology, Annals of Oncology, vol.25, issue.7, pp.1270-1283, 2014.
DOI : 10.1093/annonc/mdu022

G. Leprieur and E. , Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy, Lung Cancer, vol.79, issue.2, pp.167-172, 2013.
DOI : 10.1016/j.lungcan.2012.10.010

C. Gridelli, Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer, J. Natl. Cancer Inst, vol.91, pp.66-72, 1999.

E. Quoix, Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial, The Lancet, vol.378, issue.9796, pp.1079-1088, 2011.
DOI : 10.1016/S0140-6736(11)60780-0

URL : https://hal.archives-ouvertes.fr/hal-00718837

D. M. Jackman, Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials, Clinical Cancer Research, vol.15, issue.16, pp.5267-5273, 2009.
DOI : 10.1158/1078-0432.CCR-09-0888

D. Jackman, Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.28, issue.2, pp.357-360, 2010.
DOI : 10.1200/JCO.2009.24.7049

K. Suda, H. Mizuuchi, Y. Maehara, and T. Mitsudomi, Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation???diversity, ductility, and destiny, Cancer and Metastasis Reviews, vol.4, issue.5, pp.807-814, 2012.
DOI : 10.1007/s10555-012-9391-7

H. Vikis, EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity, Cancer Research, vol.67, issue.10, pp.4665-4670, 2007.
DOI : 10.1158/0008-5472.CAN-07-0217

J. Remon, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins, Cancer Treatment Reviews, vol.40, issue.1, pp.93-101, 2014.
DOI : 10.1016/j.ctrv.2013.06.002

C. Yun, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc. Natl. Acad. Sci. 105, pp.2070-2075, 2008.
DOI : 10.1073/pnas.0709662105

G. R. Oxnard, Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation, Clinical Cancer Research, vol.17, issue.6, pp.1616-1622, 2011.
DOI : 10.1158/1078-0432.CCR-10-2692

G. J. Riely, Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma, Clinical Cancer Research, vol.14, issue.18, pp.5731-5734, 2008.
DOI : 10.1158/1078-0432.CCR-08-0646

J. L. Bos, The ras gene family and human carcinogenesis, Mutation Research/Reviews in Genetic Toxicology, vol.195, issue.3, pp.255-271, 1988.
DOI : 10.1016/0165-1110(88)90004-8

P. A. Jänne, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study, The Lancet Oncology, vol.14, issue.1, pp.38-47, 2013.
DOI : 10.1016/S1470-2045(12)70489-8

A. Citri, K. B. Skaria, and Y. Yarden, The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003.
DOI : 10.1016/S0014-4827(02)00101-5

K. Takezawa, Mutation, Cancer Discovery, vol.2, issue.10, pp.922-933, 2012.
DOI : 10.1158/2159-8290.CD-12-0108

J. Mazières, Mutation: Epidemiologic Characteristics and Therapeutic Perspectives, Journal of Clinical Oncology, vol.31, issue.16, p.6095, 2012.
DOI : 10.1200/JCO.2012.45.6095

M. E. Arcila, Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas, Clinical Cancer Research, vol.18, issue.18, pp.4910-4918, 2012.
DOI : 10.1158/1078-0432.CCR-12-0912

T. Mitsudomi and Y. Yatabe, Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer, FEBS Journal, vol.22, issue.2, pp.301-308, 2010.
DOI : 10.1111/j.1742-4658.2009.07448.x

S. E. Wang, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors, Cancer Cell, vol.10, issue.1, pp.25-38, 2006.
DOI : 10.1016/j.ccr.2006.05.023

S. Cardarella, Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.16, pp.4532-4540, 2013.
DOI : 10.1158/1078-0432.CCR-13-0657

P. K. Paik, Mutations, Journal of Clinical Oncology, vol.29, issue.15, pp.2046-2051, 2011.
DOI : 10.1200/JCO.2010.33.1280

C. A. Pratilas, Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer, Cancer Research, vol.68, issue.22, pp.9375-9383, 2008.
DOI : 10.1158/0008-5472.CAN-08-2223

C. Birchmeier, W. Birchmeier, E. Gherardi, and G. F. Vande-woude, Met, metastasis, motility and more, Nature Reviews Molecular Cell Biology, vol.4, issue.12, pp.915-925, 2003.
DOI : 10.1038/nrm1261

C. Boccaccio and P. M. Comoglio, Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nature Reviews Cancer, vol.16, issue.8, pp.637-645, 2006.
DOI : 10.1038/nrc1912

K. Furge, Y. Zhang, and G. Vande-woude, Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Publ. Online 20 Novemb, 2000.

J. A. Engelman, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science, vol.316, issue.5827, pp.1039-1043, 2007.
DOI : 10.1126/science.1141478

J. Bean, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc. Natl. Acad. Sci, pp.20932-20937, 2007.
DOI : 10.1073/pnas.0710370104

D. R. Camidge, Efficacy and safety of crizotinib in patients with advanced c-METamplified non-small cell lung cancer (NSCLC) ASCO Meet, Abstr, vol.32, p.8001, 2014.

R. Ferracini, The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit, Oncogene, vol.10, pp.739-749, 1995.

S. Yano, Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort, J. Thorac. Oncol, 2011.

E. A. Akbay, Activation of the PD-1 pathway contributes to immune escape in EGFRdriven lung tumors, Cancer Discov, vol.3, 2013.

L. Neckers and P. Workman, Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? Clin. Cancer Res, pp.64-76, 2012.

T. Ueno, Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer, Lung Cancer, vol.76, issue.1, pp.26-31, 2012.
DOI : 10.1016/j.lungcan.2011.09.011

E. B. Garon, Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC), ASCO Meet. Abstr, vol.30, p.7543, 2012.

M. L. Johnson, -Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, Journal of Clinical Oncology, vol.33, issue.15, pp.1666-1673, 2015.
DOI : 10.1200/JCO.2014.59.7328

URL : https://hal.archives-ouvertes.fr/jpa-00210025

L. V. Sequist, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Science Translational Medicine, vol.3, issue.75, pp.75-101, 2011.
DOI : 10.1126/scitranslmed.3002003

Z. Zhang, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer, Nature Genetics, vol.88, issue.8, pp.852-860, 2012.
DOI : 10.2353/jmoldx.2010.090140

M. G. Oser, M. J. Niederst, L. V. Sequist, and J. A. Engelman, Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin, The Lancet Oncology, vol.16, issue.4, pp.165-172, 2015.
DOI : 10.1016/S1470-2045(14)71180-5

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, and D. Sargent, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

. Inca, Les tests de génétique moléculaire pour l'accès aux thérapies ciblées en 2012 -Ref : BILTESTGEN12 | Institut National Du Cancer at <http://www.e-cancer.fr/Expertises-et- publications/Catalogue-des-publications/Les-tests-de-genetique-moleculaire-pour-l-acces-aux- therapies-ciblees-en-2012>, 2012.

D. M. Jackman, Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib, Clinical Cancer Research, vol.12, issue.13, pp.3908-3914, 2006.
DOI : 10.1158/1078-0432.CCR-06-0462

M. Takeda, I. Okamoto, and K. Nakagawa, Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation???Positive Non???Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib, Journal of Thoracic Oncology, vol.9, issue.2, pp.200-204, 2014.
DOI : 10.1097/JTO.0000000000000053

A. Mansuet-lupo, Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?, Journal of Translational Medicine, vol.12, issue.1, p.131, 2014.
DOI : 10.1016/S1525-1578(10)60006-2

URL : https://hal.archives-ouvertes.fr/inserm-00998916

C. Bosc, Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC, Targeted Oncology, vol.359, issue.4, pp.247-253, 2014.
DOI : 10.1007/s11523-014-0332-y

H. J. Yoon, Repeat Biopsy for Mutational Analysis of Non???Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications, Radiology, vol.265, issue.3, pp.939-948, 2012.
DOI : 10.1148/radiol.12112613

J. Wu, Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer, International Journal of Cancer, vol.23, issue.1, pp.247-255, 2010.
DOI : 10.1002/ijc.24657

S. B. Goldberg, Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, The Oncologist, vol.18, issue.11, pp.1214-1220, 2013.
DOI : 10.1634/theoncologist.2013-0168

M. Jamal-hanjani and J. Spicer, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain, Clinical Cancer Research, vol.18, issue.4, pp.938-944, 2012.
DOI : 10.1158/1078-0432.CCR-11-2529

C. Grommes, "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer, Neuro-Oncology, vol.13, issue.12, pp.1364-1369, 2011.
DOI : 10.1093/neuonc/nor121

D. M. Jackman, Response and Resistance in a Non???Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib, Journal of Clinical Oncology, vol.24, issue.27, pp.4517-4520, 2006.
DOI : 10.1200/JCO.2006.06.6126

G. J. Riely, Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.2, pp.264-270, 2009.
DOI : 10.1200/JCO.2008.17.4656

H. A. Yu, Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, Journal of Thoracic Oncology, vol.8, issue.3, pp.346-351, 2013.
DOI : 10.1097/JTO.0b013e31827e1f83

E. Mctyre, J. Scott, and P. Chinnaiyan, Whole brain radiotherapy for brain metastasis, Surg. Neurol. Int, vol.4, pp.236-244, 2013.

J. W. Welsh, Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.31, issue.7, pp.895-902, 2013.
DOI : 10.1200/JCO.2011.40.1174

G. R. Oxnard, Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer, ASCO Meet. Abstr, vol.30, p.7547, 2012.

D. Marquez-medina, Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?, Clinical and Translational Oncology, vol.92, issue.3, pp.959-964, 2013.
DOI : 10.1007/s12094-013-1035-z

S. Kobayashi, Mutation and Resistance of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.352, issue.8, pp.786-792, 2005.
DOI : 10.1056/NEJMoa044238

J. E. Chaft, Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design, Clinical Cancer Research, vol.17, issue.19, pp.6298-6303, 2011.
DOI : 10.1158/1078-0432.CCR-11-1468

H. Akamatsu, Disease flare after gefitinib discontinuation, Respiratory Investigation, vol.53, issue.2, pp.68-72, 2015.
DOI : 10.1016/j.resinv.2014.10.005

K. Park, 1223OASPIRATION: FIRST-LINE ERLOTINIB (E) UNTIL AND BEYOND RECIST PROGRESSION (PD) IN ASIAN PATIENTS (PTS) WITH EGFR MUTATION-POSITIVE (MUT+) NSCLC, Annals of Oncology, vol.25, issue.suppl_4, pp.426-470, 2014.
DOI : 10.1093/annonc/mdu349.2

J. Yang, Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer, Lung Cancer, vol.79, issue.1, pp.33-39, 2013.
DOI : 10.1016/j.lungcan.2012.09.016

K. Nishino, A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment, Lung Cancer, vol.82, issue.2, pp.299-304, 2013.
DOI : 10.1016/j.lungcan.2013.08.009

T. Song, W. Yu, and S. Wu, Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?, Asian Pacific Journal of Cancer Prevention, vol.15, issue.1, pp.205-213, 2014.
DOI : 10.7314/APJCP.2014.15.1.205

D. B. Costa, Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib, Clinical Cancer Research, vol.14, issue.21, pp.7060-7067, 2008.
DOI : 10.1158/1078-0432.CCR-08-1455

J. Chmielecki, Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling, Science Translational Medicine, vol.3, issue.90, pp.90-59, 2011.
DOI : 10.1126/scitranslmed.3002356

J. Soria, Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial, The Lancet Oncology, vol.16, issue.8, pp.990-998, 2015.
DOI : 10.1016/S1470-2045(15)00121-7

P. A. Jänne, AZD9291 in EGFR Inhibitor???Resistant Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.18, pp.1689-1699, 2015.
DOI : 10.1056/NEJMoa1411817

L. V. Sequist, -Mutated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.18, pp.1700-1709, 2015.
DOI : 10.1056/NEJMoa1413654

S. Couraud, Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002, Clinical Cancer Research, vol.20, issue.17, pp.4613-4624, 2014.
DOI : 10.1158/1078-0432.CCR-13-3063

O. Gautschi, Circulating Deoxyribonucleic Acid As Prognostic Marker in Non???Small-Cell Lung Cancer Patients Undergoing Chemotherapy, Journal of Clinical Oncology, vol.22, issue.20, pp.4157-4164, 2004.
DOI : 10.1200/JCO.2004.11.123

J. Luo, L. Shen, and D. Zheng, Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis, Scientific Reports, vol.23, 2014.
DOI : 10.1038/srep06269